Comparing the effects of cottonseed oil and matched PUFA on cholesterol levels
Official title: Health Effects of Cottonseed Oil Versus Matched Composition Diets in Humans
Run by University of Georgia · NCT06382298 · Data updated 2026-11-12
This study is testing whether drinking meal replacement shakes with cottonseed oil can help lower cholesterol levels in adults at risk for heart disease compared to shakes with a different type of healthy fat.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 25 Years to 75 Years |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | University of Georgia Academic / other |
| Locations | 1 site (Athens, Georgia) |
| Status | Recruiting |
| Started | August 31, 2024 |
| Main results expected | December 2026 |
| Study ends | May 2028 |
| Registry record updated | September 9, 2026 |
| Trial ID | NCT06382298 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 25-75 with elevated cholesterol levels or overweight/obesity.
✕Probably not a fit
Patients with familial hypercholesterolemia or those on hormone replacement therapy for less than two years may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effects of cottonseed oil (CSO) compared to a matched polyunsaturated fatty acid (PUFA) diet on lipid metabolism and chronic disease risk markers in adults at increased risk for cardiovascular disease. Participants will consume meal replacement shakes containing different oils for 28 days and attend regular visits for blood draws and body measurements. The study aims to determine if CSO can improve fasting and postprandial lipid profiles and other health markers compared to a control diet. This double-blinded, randomized control trial will help clarify the potential benefits of CSO in dietary interventions.
Why it matters
Potential benefit: If successful, this study could provide a dietary intervention that significantly improves cholesterol levels and reduces cardiovascular disease risk.
How similar studies have gone: Previous studies have shown promising results with dietary interventions involving fatty acids, suggesting potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 25-75 year-old men and women at increased risk for cardiovascular disease. Increased risk for cardiovascular disease will be defined by either elevated cholesterol profiles -or- overweight/obesity. * Elevated cholesterol profiles will be defined as: -"Borderline High" and/or "at risk" in two of more of the following variables (total cholesterol: 180-239 mg/dL, LDL cholesterol 110-159 mg/dL, triglycerides 130-199 mg/dL) --or-- * "High" in total cholesterol (240 mg/dL and higher), LDL (160 mg/dL or higher), or triglycerides (between 200-350 mg/dL). Overweight/obesity will be defined by body mass index \>25 kg/m². Exclusion Criteria: * Probable familial hypercholesterolemia, defined by: total cholesterol greater than 290 mg/dL or LDL levels greater than 190 mg/dL plus a family history of myocardial infarction (MI) before 50 years of age in a 2nd-degree relative or below age 60 in a 1st-degree relative. * Women on hormone replacement therapy less than 2 years. * Women who are pregnant * individuals who regularly exercise more than 3h/w * weight gain or loss of more than 5% body weight in the past 3 months * plans to begin a weight loss/exercise regimen during the trial * history of medical or surgical events that could affect digestion or swallowing * gastrointestinal surgeries, conditions, or disorders * any chronic diseases (including moderate to severe asthma, chronic lung disease, and kidney disease), * metabolic disease * atherosclerosis * previous MI or stroke * cancer * fasting blood glucose levels greater than 126 mg/dL * blood pressure greater than 180/120 mmHg * medication use affecting digestion an absorption, metabolism (e.g. thyroid meds), lipid-lowering medications, medications for diabetes, steroid/hormone therapies, or current antibiotic cycles * medically prescribed or special diets * Food allergies (specific to the foods in the study, including wheat, dairy, and cottonseed oil) * fish oil supplements * excessive alcohol use (greater than 3 drinks/day for men; greater than 2 drinks/day for women) * tobacco or nicotine use * underweight BMI (\<18.5 kg/m²)
Where it's running
-
University of Georgia
Athens, Georgia, United States Recruiting
Study contacts
- Principal investigator: Jamie Cooper, PhD — University of Georgia
- Study coordinator: Jamie Cooper, PhD
- Email: jamie.cooper@uga.edu
- Phone: 706-542-4378
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Intermittent cottonseed oil intake to improve cholesterol and metabolic risk
This trial will test whether taking cottonseed oil three times a week at two different doses can improve fasting and after-meal blood lipids and other risk markers in adults with high cholesterol or who are overweight.
-
Daily postbiotic gummy plus nutrition advice for adults with overweight or obesity
This project will test whether taking a daily postbiotic gummy together with nutritional advice helps adults with overweight or obesity improve body composition, glucose metabolism, and gut microbiota.
-
Observational study of achieving LDL targets with Rovazet tablets in dyslipidemia
This study follows patients with dyslipidemia who are prescribed Rovazet to see how well reaching LDL targets works in routine care over 48 weeks.
-
How flour milling methods affect blood sugar and gut feelings after eating bread
In healthy adults who eat bread regularly, this study tests whether bread made from stone-milled flour leads to a smaller rise in blood sugar and fewer gut symptoms than bread made from roller-milled flour.
-
Nutrition support to improve dietary diversity in adults who are underweight or overweight/obese
A community-based nutrition program will be tested in adults in Cambodia to see if it improves dietary diversity and if the program is acceptable and feasible to run.
-
Early Triple Lipid-Lowering Therapy After ACS
This trial tests whether adding bempedoic acid to high-intensity statin and ezetimibe within 72 hours after PCI helps more adults with acute coronary syndrome reach LDL-C goals than the standard two-drug approach.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.